April 25 (Bloomberg) -- Novartis AG’s multiple sclerosis pill Gilenya won final approval from England’s health-cost agency for some patients after the company agreed to a discounted price.
The National Institute for Health and Clinical Excellence, or NICE, recommended Gilenya as a treatment option for some adults with relapsing-remitting multiple sclerosis, a form of the disease in which symptoms worsen and improve periodically, it said in a statement today. The decision confirms a preliminary ruling made last month.
Gilenya costs about 19,196 pounds ($30,970). NICE isn’t disclosing the size of the discount that Novartis offered.
To contact the reporter on this story: Phil Serafino in Paris at email@example.com
To contact the editor responsible for this story: Phil Serafino at firstname.lastname@example.org